Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Pfizer is taking a stake of roughly 9.9%, worth $200 million, in China-based CStone Pharmaceuticals. The investment is part of a broader collaboration to develop the biotech firm’s PD-L1 antibody sugemalimab in China and bring other cancer therapies to market there. Pfizer will lead marketing of sugemalimab, an immunotherapy in several mid-to-late-stage studies to treat tumors like lung, gastric, and esophageal, which occur at high rates in China. As part of the deal, the partners will pick late-stage cancer therapies from Pfizer’s pipeline or from outside partners to develop in China.
This article has been sent to the following recipient: